Evaluating the Use of Microarray Pharmacogenetic Testing in Patients With Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"
- Conditions
- Cancer
- Sponsor
- Wake Forest University Health Sciences
- Enrollment
- 120
- Locations
- 2
- Primary Endpoint
- Number of potentially actionable results based on pharmacogenomic (PGx) test
- Status
- Recruiting
- Last Updated
- 2 months ago
Overview
Brief Summary
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Detailed Description
This is a prospective, non-randomized, Phase 2 study. The target population is adults ≥18 years of age who have received or will be receiving standard of care single-gene DPYD (dihydropyrimidine dehydrogenase) PGx testing to help guide dosing for their cancer treatment. Pharmacogenes that will be reported back to participants and providers from the microarray test are expected to take approximately one week and will be evaluated by the PGx team and uploaded to the participant's electronic medical record (EMR). Only clinically actionable results per CPIC and FDA guidelines will be included in the participant report. Participants will be followed on study for approximately 6 months to collect data on the number of drug prescriptions with known drug-gene interactions and potentially actionable results, BPAs fired, and actions taken due to BPAs.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Written informed consent and HIPAA authorization for release of personal health information.
- •Age ≥ 18 years at the time of consent.
- •Eligible for standard of care single-gene DPYD testing (i.e., receiving or expected to receive a fluoropyrimidine-based chemotherapy regimen). The potential participant meets inclusion criteria if the standard of care single-gene DPYD test is planned or previously ordered. If previously ordered, consent must occur no later than 60 days from the date the DPYD results were available.
- •Willing to provide additional buccal swabs if residual DNA from previous DPYD testing is inadequate for microarray testing.
Exclusion Criteria
- •History of prior allogeneic hematopoietic cell transplantation or liver transplantation
Arms & Interventions
Pharmacogenomic Testing
A pharmacogenomic (PGx) microarray (multi-gene) panel will be performed to test for genetic variations in genes related to drug response.
Intervention: Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"
Outcomes
Primary Outcomes
Number of potentially actionable results based on pharmacogenomic (PGx) test
Time Frame: Baseline
A potentially actionable result refers to any genotype or phenotype that is associated with specific drug-gene interactions from the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines or the FDA's Table of Pharmacogenetic Associations. The number of potentially actionable results is a count variable that represents the total occurrences of such genotypes or phenotypes identified in a participant.
Secondary Outcomes
- The presence of at least one drug-gene interaction(Baseline, at 3 months and at 6 months after receiving the microarray profiling results)
- The presence of at least one PGx best practice advisory (BPA) alert(within 6 months of receiving the microarray profiling results)
- Taking actions from PGx best practice advisory alerts(within 6 months of receiving the microarray profiling results)
- Percentage of prescriptions that trigger PGx best practice advisory (BPA) alerts(within 6 months of receiving the microarray profiling results)